Business News • PR NewsWire • Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction

Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction

Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction

PARIS and TARRYTOWN, N.Y., Oct. 16, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9...

View More : http://www.prnewswire.com/news-releases/sanofi-and-regeneron-report-positive-top-line-results-with-alirocumab-from-first...

Releted News by prnewswire

Frost & Sullivan Partners With IRDA, i2M and MDeC to Organise the Iskandar Malaysia Case Challenge 2013

Get LED lighting connected to the Internet of Things with new ZigBee® Light Link™ development kit from TI